| Drug Type Small molecule drug | 
| Synonyms Metformin/nateglinide, Nateglinide/metformin | 
| Action activators, blockers | 
| Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), Potassium channel blockers, VGKCs blockers(Voltage-gated potassium channel blockers) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC19H27NO3 | 
| InChIKeyOELFLUMRDSZNSF-BRWVUGGUSA-N | 
| CAS Registry105816-04-4 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 1 | South Korea  | - | 





